# Dassault Systemes Buys ArisGlobal for 1,8 Billion Dollars to Close the Gap Between the Molecule and the Patient > The French group is paying cash for a compliance platform that handles more than 12 million patient safety reports a year, betting that the value in life sciences software now sits in connecting the data rather than in the software itself. - Source: Italian Insider - Canonical URL: https://italianinsider.net/en/article/dassault-systemes-arisglobal-acquisition - Author: Chiara Ricci - Section: Tech - Other edition: https://italianinsider.net/article/dassault-systemes-arisglobal-acquisition - Published: 2026-08-04T15:00:00.000Z - Updated: 2026-08-04T15:00:00.000Z - Tags: Dassault Systemes, ArisGlobal, Life sciences, Artificial intelligence --- Dassault Systemes has signed a definitive agreement to acquire ArisGlobal, which builds artificial intelligence native enterprise compliance platforms for the life sciences industry. The French group will pay about 1,8 billion dollars in cash at closing, with up to a further 200 million tied to multi year targets for revenue derived from artificial intelligence. The board approved the deal unanimously and completion is expected in the second half of 2026, subject to regulatory clearances and the usual conditions. The logic is about joining up what the industry has kept apart. Dassault Systemes, founded in 1981 and built on the idea of virtual worlds that improve real ones, brings modelling, simulation, clinical trial, manufacturing and quality expertise. ArisGlobal brings regulated operations and the management of evidence gathered in the real world. Put together, the aim is a single stream of data and knowledge running the length of a therapy's life cycle rather than a set of disconnected systems. ArisGlobal is not a small addition. Its platform covers regulatory affairs, pharmacovigilance, quality and medical affairs, and serves more than 200 customers, among them half of the world's fifty largest biopharmaceutical companies, alongside biotech and medtech firms, contract research organisations and national health authorities. The core platform is embedded in critical business processes and handles more than 12 million patient safety reports a year. The company employs over 1.300 people and expects revenue of 175 million dollars in 2026. Its NavaX platform is the piece Dassault Systemes is buying for. It puts clinical grade artificial intelligence to work at scale inside heavily regulated environments, with productivity gains the company puts above 30 percent, automating complex processes, improving data quality, strengthening compliance and producing evidence that can be relied on for decisions across a product's life. Pascal Daloz, chief executive and chairman of Dassault Systemes, said the plan to virtualise the industry has never been more relevant, and that joining real world evidence to the group's modelling and simulation work sharply improves its ability to address the current problems of drug development. Aman Wasan, chief executive of ArisGlobal, framed it as a bet against better software: the industry's future, in his account, will be built on genuinely connected intelligence rather than on improved tools, after decades in which research, development and regulated operations ran on fragmented systems and disconnected data. Financially the deal is meant to pay for itself quickly. ArisGlobal's margins are described as consistent with the group's own, and the acquisition is expected to add to both revenue growth and earnings per share from the first year. It will be funded entirely from cash on the balance sheet, which leaves the group's financial flexibility intact. --- Originally published by Italian Insider. Free to cite with attribution and a link to https://italianinsider.net/en/article/dassault-systemes-arisglobal-acquisition.